Navigation Links
Study reveals how the world's first drug for amyloid disease works
Date:5/29/2012

y patients, cardiomyopathy can present later in the course of the disease.

In transthyretin amyloid diseases that present primarily as a cardiomyopathy, doctors have been able to stave off heart failure with a liver and heart transplant; familial amyloid polyneuropathy patients receiving a liver transplant can benefit, since the liver is the primary source of mutant, disease-associated TTR. For the 90 percent of patients surviving transplantation, this surgical form of gene therapy slows familial amyloid polyneuropathy progression, but does not stop it as the wild type transthyretin protein can continue to form amyloid.

Left untreated, the TTR amyloidoses are relentlessly progressive and inevitably fatal, with a course of about a decade from initial symptoms to death.

The Search for Treatments

Kelly began searching for TTR-amyloidogenesis-inhibitors in the mid 1990s, and a few years later began to focus on a family of TTR-binding compounds, the so-called benzoxazoles, whose basic design would further be elaborated into tafamidis using a structure-based drug design paradigm. In 2003, Kelly co-founded a Cambridge, Massachusetts-based biotechnology startup, FoldRx Pharmaceuticals (now a fully owned subsidiary of Pfizer), to develop these compounds and optimize one of them into an orally available drug for the treatment of the TTR amyloidoses. The result was tafamidis meglumine, whose preclinical tests remained unpublished until now.

Kelly and his colleagues designed tafamidis to bind to the natural, functional TTR structure (mutant and wild type), in a way that prevents it from deviating from this natural, functional form into the amyloid state. TTR's natural, functional form is a "tetramer" made from four copies of the protein. Amyloidosis occurs when these tetramers come apart and the individual TTR proteins ("monomers") undergo shape changes enabling them to misassemble into dysfunctional amyloid aggregates. Incl
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Study finds emissions from widely used cookstoves vary with use
2. NIH-funded study examines use of mobile technology to improve diet and physical activity behavior
3. Study provides new insights into structure of heart muscle fibers
4. U of M study finds titan cells protect Cryptococcus
5. Variations of a single gene can lead to too much or too little growth, study shows
6. Yale study concludes public apathy over climate change unrelated to science literacy
7. T cells hunt parasites like animal predators seek prey, a Penn Vet-Penn Physics study reveals
8. Study finds voter genetics may predict election outcomes
9. Army study: DNA vaccine and duck eggs protect against hantavirus disease
10. New HealthFocus® International Study Reveals Five Very Different Weight Management Consumers
11. New study shows how nanotechnology can help detect disease earlier
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study reveals how the world's first drug for amyloid disease works
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... cellsas indicated by a molecular imaging techniquecould tell researchers ... headaches and psychosis in schizophrenic patients, occur and provide ... two studies published in the November issue of the ... positron emission tomography (PET)a noninvasive molecular imaging techniqueresearchers were ...
... When 100 m sprinters launches themselves from the starting blocks, ... few strides. Acceleration through the first few strides is the ... by an American football star, who sprints in his position ... his technique and training regime, Piazza decided to focus on ...
... have confirmed that the largest bat in Europe, ... the Late Pleistocene (between 120,000 and 10,000 years ago). ... at Abrc Roman (Barcelona) prove that this bat had ... than it does today, having declined due to the ...
Cached Biology News:Unlocking mysteries of the brain with PET 2Short heels make elite sprinters super speedy 2The largest bat in Europe inhabited northeastern Spain more than 10,000 years ago 2
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... - Injured soldiers in Iraq and Afghanistan are becoming ... a Madison-based company is developing counter-measures. , ,With a ... U.S. Army in hand, ConjuGon, Inc. ... antibiotic-resistant bacterial infections. , ,"We are pleased that the ...
... White Sox this year and as for the Cubs ... What we cannot "wait until next year" for is some real ... Chicago. , ,There should be as much buzz, if not more, ... teams that didn't even make the playoffs, but maybe the media ...
... - Patent law is esoteric territory, but a Madison court ... in the process it might be giving smaller drug companies ... , ,The most recent example occurred last month. After a ... jury in U.S. District Court for the Western District ...
Cached Biology Technology:Wait `till next year OK for baseball, not broadband 2Wait `till next year OK for baseball, not broadband 3Wait `till next year OK for baseball, not broadband 4Wait `till next year OK for baseball, not broadband 5With patents, Wisconsin court gaining reputation as a "rocket docket" 2With patents, Wisconsin court gaining reputation as a "rocket docket" 3With patents, Wisconsin court gaining reputation as a "rocket docket" 4
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: